Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17533446 | 0.93 | TSHR (0.42) | TSHRALDH1A1CYP3A4RECQLMAPK1 | |
| SCHEMBL7786706 | 0.85 | ALDH1A1 (0.50) | TSHRALDH1A1CYP3A4MAPK1VCAM1 | |
| SCHEMBL3175084 | 0.82 | TSHR (0.48) | TSHRALDH1A1CYP3A4RECQLGPR35 | |
| SCHEMBL29804082 | 0.82 | TSHR (0.48) | TSHRALDH1A1CYP3A4RECQLGPR35 | |
| SCHEMBL15927413 | 0.82 | ALDH1A1 (0.49) | TSHRALDH1A1CYP3A4RECQLGPR35 | |
| SCHEMBL14809875 | 0.82 | CYP1A2 (0.49) | TSHRALDH1A1GPR35PPIAPDK1 | |
| SCHEMBL14810031 | 0.82 | TSHR (0.37) | TSHRALDH1A1CYP3A4RECQLGPR35 | |
| SCHEMBL12658937 | 0.81 | PDK1 (0.45) | TSHRALDH1A1CYP3A4GPR35MAPK1 | |
| SCHEMBL1425442 | 0.81 | ALDH1A1 (0.50) | TSHRALDH1A1CYP3A4MAPK1VCAM1 | |
| SCHEMBL5068830 | 0.80 | PPIA (0.47) | TSHRALDH1A1CYP3A4RECQLGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | PAK2, PAK3, PAK1 | TSHR 3372/4885ALDH1A1 2927/4885CYP3A4 4883/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | TSHR 3155/4885ALDH1A1 1936/4885CYP3A4 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.